Abl bio announces grabody-b brain delivery platform license agreement with gsk to develop novel medicines for neurodegenerative diseases

- abl bio and gsk enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - programs will leverage abl bio's grabody-b platform technology to effectively deliver molecules a cross the blood-brain barrier - abl bio to receive up to £77 million in upfront and near-term payments  seongnam, south korea , april 6, 2025 /prnewswire/ -- abl bio inc. (kosdaq: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a worldwide licensing agreement enabling gsk to develop novel medicines for neurodegenerative diseases by utilizing abl bio's blood-brain barrier (bbb) shuttle platform, grabody-b. the agreement aims to develop multiple programs for novel targets across therapeutic modalities including antibody, polynucleotide or oligonucleotides, such as sirna and asos, to address significant unmet medical needs of patients suffering from neurodegenerative conditions.
ABL Ratings Summary
ABL Quant Ranking